# A Worldwide Antihistamine-Refractory Chronic Urticaria Patient Evaluation in Latin America and Canada (AWARE-LACan)

> **NCT02626221** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 497 (actual)

## Conditions studied

- Chronic Urticaria

## Interventions

- **OTHER:** Non Interventional Study

## Key facts

- **NCT ID:** NCT02626221
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-24
- **Primary completion:** 2018-03-21
- **Final completion:** 2018-03-21
- **Target enrollment:** 497 (ACTUAL)
- **Last updated:** 2018-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02626221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02626221, "A Worldwide Antihistamine-Refractory Chronic Urticaria Patient Evaluation in Latin America and Canada (AWARE-LACan)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02626221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*